Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;61(10):1471-1473.
doi: 10.1007/s40262-022-01159-6. Epub 2022 Jul 27.

Influence of Darolutamide on Cabazitaxel Systemic Exposure

Stefan A J Buck  1 , Niels A D Guchelaar  2 , Peter de Bruijn  2 , Inge M Ghobadi Moghaddam-Helmantel  2 , Esther Oomen-de Hoop  2 , Hans M Westgeest  3 , Paul Hamberg  4 , Danielle Mathijssen-van Stein  4 , Martijn P Lolkema  2 , Stijn L W Koolen  2   5 , Ronald de Wit  2 , Ron H J Mathijssen  2
Affiliations

Influence of Darolutamide on Cabazitaxel Systemic Exposure

Stefan A J Buck et al. Clin Pharmacokinet. 2022 Oct.
No abstract available

PubMed Disclaimer

References

    1. Buck SAJ, Koolen SLW, Mathijssen RHJ, de Wit R, van Soest RJ. Cross-resistance and drug sequence in prostate cancer. Drug Resist Updat. 2021;56: 100761. https://doi.org/10.1016/j.drup.2021.100761 . - DOI - PubMed
    1. Mout L, van Royen ME, de Ridder C, Stuurman D, van de Geer WS, Marques R, et al. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer. EBioMedicine. 2021;5(73): 103681. https://doi.org/10.1016/j.ebiom.2021.103681 . - DOI
    1. Belderbos BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, van der Meer N, de Bruijn P, et al. Influence of enzalutamide on cabazitaxel pharmacokinetics: a drug-drug interaction study in metastatic castration-resistant prostate cancer (mCRPC) patients. Clin Cancer Res. 2018;24(3):541–6. https://doi.org/10.1158/1078-0432.CCR-17-2336 . - DOI - PubMed
    1. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383(11):1040–9. https://doi.org/10.1056/NEJMoa2001342 . - DOI - PubMed
    1. Zurth C, Koskinen M, Fricke R, Prien O, Korjamo T, Graudenz K, et al. Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019;44(6):747–59. https://doi.org/10.1007/s13318-019-00577-5 . - DOI - PubMed - PMC

Publication types

Associated data

LinkOut - more resources